NCT07715188 Low Dose Radiotherapy for Osteoarthritis
| NCT ID | NCT07715188 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Osteoarthitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 113 participants |
| Start Date | 2026-06-24 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 113 participants in total. It began in 2026-06-24 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single institution, multi-site, single arm prospective study will enroll patients with a history of OA and assess changes in pain and function after treatment with LDRT as measured by patient-reported outcomes.
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Diagnosis of OA \>3 months in hips, knees, hands, shoulders, ankles or elbows. * Refractory to standard of care therapies for OA or those who are being considered for more aggressive interventional treatment such as joint replacement, but more conservative treatment is desired. * Provision of signed and dated informed consent. Exclusion Criteria: * Unable to reasonably complete study instruments.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07715188 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Osteoarthitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07715188 currently recruiting?
Yes, NCT07715188 is actively recruiting participants. Contact the research team at Marlowe.Estioko@Pennmedicine.upenn.edu for enrollment information.
Where is the NCT07715188 trial being conducted?
This trial is being conducted at Philadelphia, United States, Philadelphia, United States.
Who is sponsoring the NCT07715188 clinical trial?
NCT07715188 is sponsored by Abramson Cancer Center at Penn Medicine. The trial plans to enroll 113 participants.